India has identified a supplier of toxic ingredients linked to cough syrup deaths

Drug manufacturers were told to stop using propylene glycol sourced from a Delhi-based chemical plant

We may earn a commission from links on this page.
Police officers outside the headquarters of Marion Pharmaceuticals
Police officers outside the headquarters of Marion Pharmaceuticals
Photo: ANUSHREE FADNAVIS (Reuters)

The Indian government has made progress in its investigation into the manufacturing of cough syrup products that have caused the deaths of 19 children in Uzbekistan.

Pharmaceutical manufacturers were told to stop using propylene glycol sourced from a Delhi-based chemical plant operated by Maya Chemtech India Private, which supplied cough syrup ingredients to Marion Biotech.

Advertisement

Government officials in Uzbekistan first linked the deaths to Marion’s cough syrups Ambronol and DOK-1 Max in December. Last week, Indian authorities arrested three Marion employees after tests in a government laboratory found that 22 of 36 samples had unacceptable amounts of diethylene glycol or ethylene glycol, leading to a suspension of the company’s production. Ashish Kondal, the drug inspector investigating the case, alleged the company disposed of materials and records related to the manufacturing process.

Advertisement

Diethylene glycol and ethylene glycol are industrial versions of the glycerine found in propylene glycol, which is a necessary ingredient in making cough syrup. While cheaper than pure glycerine, the alternative ingredients are nephrotoxic and can cause organ failure, especially in children.

Advertisement

Representatives for Marion Biotech and Maya Chemtech were not immediately available for comment.

Indian cough syrup linked to child deaths last year

The substitution of glycerine with industrial alternatives in cough syrup has been linked to child deaths around the world, including the deaths of 99 children in Indonesia last year. That incident prompted the Indonesian government to ban all syrup-based medicine.

Advertisement

Last fall, 66 children died in the Gambia after taking cough medicine made by Maiden Pharmaceuticals—an Indian company based in Haryana—that also included elevated levels of diethylene glycol and ethylene glycol, according to testing done by the World Health Organization.

However, Maiden was cleared in December by the Indian government, which found the cough syrup met regulatory standards. The firm is looking to restart production.

Advertisement


Related stories:

💊 India’s pharma sector is among the most vulnerable to the Russia-Ukraine war’s effects

Advertisement

🔌 India fears a torrid summer of long power cuts

📈 How Indian YouTube influencers are manipulating the stock market